Most Read Articles
3 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, 3 days ago
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Impact of metabolic syndrome on breast cancer risk varies by age

30 Oct 2020

The presence of metabolic syndrome portends a heightened risk of developing breast cancer among postmenopausal women but appears to be protective among those who are younger, a retrospective study has found.

In a cohort of 13,377,349 women aged >19 years (64,535,186 person-years) from Korean National Health Insurance Service, 3,578,546 (26.8 percent) had metabolic syndrome. A higher number of women with the medical condition were aged >50 years and had body mass index ≥25 kg/m2. On the other hand, those without metabolic syndrome were more likely to smoke, drink alcohol, exercise, and have low income.

There were 79,447 and 8,300 women who developed invasive and in situ breast cancer, respectively, regardless of metabolic syndrome. In multivariable Cox proportional hazards models, the risk of all breast cancer types was low in the presence of metabolic syndrome (hazard ratio [HR], 0.954, 95 percent confidence interval [CI], 0.939–0.970).

However, the estimates differed by age such that the breast cancer risk associated with metabolic syndrome was low among women aged ≤50 years (HR, 0.915, 95 percent CI, 0.892–0.939) but high among women aged >50 years, especially those >55 years of age (HR, 1.146, 95 percent CI, 1.123–1.170).

Furthermore, as the number of metabolic syndrome components increased, the risk soared and dropped further in the older age group and ≤50-year age groups, respectively.

The findings highlight a need to assess breast cancer risks in women with metabolic syndrome.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, 3 days ago
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.